Delivery Order SPE2DB22D1041-SPE2DB24FUDW9

Award Date 9/24/24
Potential Completion Date 9/25/24
Potential Value $2.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,908.68, is for the delivery of 4,566,615,580 units of 4 mg Ondansetron HCL tablets. The contract is a firm fixed-price delivery order, without any set-aside designation, and has an ultimate completion date of December 5, 2024. Amerisourcebergen holds a larger Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,990.87 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets. The contract has an ultimate completion date of December 4, 2024 and was awarded on December 3, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of 4,565,481,035 tablets of Ondansetron HCL 4 mg to the Defense Logistics Agency (DLA). The $3,874.39 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on August 16, 2024 with a completion date of August 19, 2024. The contract is not designated with a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November...
This federal contract award from the Defense Logistics Agency (DLA) is a Delivery Order valued at $1,929.28 with a completion date of December 15, 2023. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, to supply 4,563,107,422 units of Ondansetron HCL 4 mg tablets. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,626,504 units of 4 mg Ondansetron HCL tablets. The firm-fixed-price delivery order, valued at $18,464.18, has a completion date of December 6, 2024. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,865.48 firm fixed-price delivery order is for the supply of 4 mg ondansetron HCL tablets. The contract has an ultimate completion date of January 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,657.32 firm fixed-price delivery order covers the supply of 4567280066 - Ondansetron HCL 4 MG Tablet 30s, with a period of performance through February 18, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $4,555.91, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of 4,566,148,838 units of Ondansetron HCL 4 mg Tablets in 30-count packages. The award has an ultimate completion date of October 21, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ondansetron HCL 4 mg tablets. The $2,266.29 firm fixed-price contract has a completion date of May 16, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award, valued at $2,294.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for 4,568,013,154 units of the medication Ondansetron HCL 4 mg tablet, with a firm fixed price. The contract has an ultimate completion date of April 24, 2025 and was awarded on April 23, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB22D1041
    Indefinite Delivery Contract
  • SPE2DB22D1041-SPE2DB24FUDW9
    Delivery Order

This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $2,734.61 for the supply of Ondansetron HCL 4 mg tablets. The award was made to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, and does not utilize any set-aside designations. The contract has an ultimate completion date of September 25, 2024.

This delivery order is likely part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a wide range of essential pharmaceutical and medical supplies from Amerisourcebergen to support military treatment programs and facilities worldwide. Amerisourcebergen also holds a notable IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.

Generated 12/24/24, 9:22 AM